CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Eplerenone +2 moredrug
Likely dose
Eplerenone 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02740179
NCT02740179N/ACompleted
CompareCT.gov

Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study

Massachusetts General Hospital·interventional·Posted Apr 15, 2016·Updated Jun 6, 2023

In Brief

A clinical study evaluating Eplerenone, Placebo, and 1 other intervention for HIV. Completed, enrolled 40 participants across 1 site.

Detailed Summary

HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals. A hormone called aldosterone, which regulates blood pressure and sodium balance, is elevated in the HIV population in association with with increased belly fat and altered glucose metabolism. Elevations in aldosterone hormone may also be associated with abnormal blood flow, inflammation, and coronary plaque in the heart. This study is being conducted to evaluate whether therapies to reduce the actions of aldosterone may decrease the burden and progression of heart disease in the HIV population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 15, 2016
Enrollment StartJan 1, 2017
Primary CompletionMar 17, 2022
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 10.2 years ago

Interventions

Eplerenonedrug

Eplerenone 50mg by mouth twice daily

Placebodrug

Placebo by mouth twice daily

Lifestyle Modificationbehavioral

Counseling regarding diet and healthy activity